Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Serum omentin-1 as a predictor of activity in Crohn’s disease

The Egyptian Journal of Internal Medicine volume 31, pages 514–521 (2019)Cite this article

Abstract

Background and aim

Crohn’s disease (CD) is associated with alterations in fat mass and fat distributions, with changed productions of adipokines, including omentin-1. Omentin-1 may be involved in the pathogenesis of inflammatory bowel disease. The aim was to determine the serum and mucosal omentin-1 levels in CD patients and to evaluate its potential as a marker for disease activity.

Patients and methods

Seventy-five adult consecutive outpatients, with a confirmed diagnosis of CD, and 45 age-matched, sex-matched, and BMI-matched healthy volunteers were enrolled in this study after written conscious consent and approval by the Institutional Review Board of Mansoura University. CD was diagnosed by conventional clinical, radiological, endoscopic, and histopathological criteria. Serum levels and mucosal mRNA expression of omentin-1 were measured by commercially available kits according to the manufacturer’s protocols.

Results

Serum omentin-1 and its mucosal gene expression were significantly lower in patients with CD (53.3±12.8) than in healthy controls (72.7±16.8, P<0.0001). Moreover, serum omentin-1 levels were significantly lower in patients with active CD (36.2±9.6) than in patients in remission (69.2±14.4, P≤0.0001). No significant differences were demonstrated between patients in remission and healthy controls (P>0.05). In CD patients, the decrease in serum omentin-1 was associated with a significantly higher BMI, C-reactive protein, erythrocyte sedimentation rate, Crohn’s disease activity index, simplified endoscopic score for CD and inflammation scores (P≤0.05). Moreover, omentin-1 was much superior to C-reactive protein in predicting CD activity and severity.

Conclusion

Serum and mucosal expression of omentin-1 might be a reliable surrogate noninvasive marker of disease activity in CD with significantly high sensitivity, specificity, and diagnostic accuracy.

References

  1. Goh J, O’Morain CA. Review article: nutrition and adult inflammatory bowel disease. Aliment Pharmacol Ther 2003; 17:307–320.

    Article  CAS  Google Scholar 

  2. Bamias G, Nyce MR, De La Rue SA, Cominelli F. New concepts in the pathophysiology of inflammatory bowel disease. Ann Intern Med 2005; 143:895–904.

    Article  CAS  Google Scholar 

  3. Ahualli J. The fat halo sign. Radiology 2007; 242:945–946.

    Article  Google Scholar 

  4. Schäffler A, Schölmerich J, Büchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue – emerging role in intestinal and mesenteric diseases. Nat Clin Pract Gastroenterol Hepatol 2005; 2:103–111.

    Article  Google Scholar 

  5. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol 2005; 115:911–919.

    Article  CAS  Google Scholar 

  6. Tan BK, Adya R, Randeva HS. Omentin: a novel link between inflammation, diabesity, and cardiovascular disease. Trends Cardiovasc Med 2010; 20:143–148.

    Article  CAS  Google Scholar 

  7. Fasshauer M, Bluher M. Adipokines in health and disease. Trends Pharmacol Sci 2015; 36:461–470.

    Article  CAS  Google Scholar 

  8. Best WR, Becktel JM, Singleton JW, Kern F. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976; 70:439–444.

    CAS  PubMed  Google Scholar 

  9. Schoepfer AM, Beglinger C, Straumann A, Trummler M, Vavricka SR, Bruegger LE, Seibold F. Fecal calprotectin correlates more closely with the Simple Endoscopic Score for Crohn’s disease (SES-CD) than CRP, blood leukocytes, and the CDAI. Am J Gastroenterol 2010; 105:162.

    Article  CAS  Google Scholar 

  10. Ponchel F, Toomes C, Bransfield K, Leong FT, Douglas SH, Field SL, et al. ‘Real-time PCR based on SYBR-Green I fluorescence: an alternative to the TaqMan assay for relative quantification of gene rearrangements, gene amplifications and micro gene deletions‘ (w). BMC Biotechnol 2003; 3:18.

    Article  Google Scholar 

  11. Jaikanth C, Gurumurthy P, Cherian KM, Indhumathi T. Emergence of omentin as a pleiotropic adipocytokine. Exp Clin Endocrinol Diabet 2013; 121:377–383.

    Article  CAS  Google Scholar 

  12. Lahiff C, Safaie P, Awais A, Akbari M, Gashin L, Sheth S, et al. The Crohn’s disease activity index (CDAI) is similarly elevated in patients with Crohn’s disease and in patients with irritable bowel syndrome. Aliment Pharmacol Therap 2013; 37:786–794.

    Article  CAS  Google Scholar 

  13. Lewis JD. The utility of biomarkers in the diagnosis and therapy of inflammatory bowel disease. Gastroenterology 2011; 140:1817–1826.

    Article  CAS  Google Scholar 

  14. Zhou JP, Tong XY, Zhu LP, Luo JM, Luo Y, Bai YP, et al. Plasma omentin-1 level as a predictor of good coronary collateral circulation. J Atheroscler Thromb 2017; 24:940–948.

    Article  CAS  Google Scholar 

  15. Kurt OK, Tosun M, Alcelik A, Yilmaz B, Talay F. Serum omentin levels in patients with obstructive sleep apnea. Sleep Breath 2014; 18:391–395.

    Article  Google Scholar 

  16. Aleksandrova K, di Giuseppe R, Isermann B, Biemann R, Schulze M, Wittenbecher C, et al. Circulating omentin as a novel biomarker for colorectal cancer risk: data from the EPIC-potsdam cohort study. Cancer Res 2016; 76:3862–3871.

    Article  CAS  Google Scholar 

  17. Sit M, Aktas G, Yilmaz EE, Alcelik A, Terzi EH, Tosun M. Effects of the inflammatory response on serum omentin levels in early acute and chronic pancreatitis. Clin Ter 2014; 165:e148–e152.

    CAS  PubMed  Google Scholar 

  18. Zhou JY, Chan L, Zhou SW. Omentin: linking metabolic syndrome and cardiovascular disease. Curr Vasc Pharmacol 2014; 12:136–143.

    Article  CAS  Google Scholar 

  19. Yilmaz Y, Yonal O, Kurt R, Alahdab YO, Eren F, Ozdogan O, et al. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease. Scand J Gastroenterol 2011; 46:91–97.

    Article  CAS  Google Scholar 

  20. Lu Y, Zhou L, Liu L, Feng Y, Lu L, Ren X, et al. Serum omentin-1 as a disease activity marker for Crohn’s disease. Dis Markers 2014; 2014:162517.

    Article  Google Scholar 

  21. Harada K, Shibata R, Ouchi N, Tokuda Y, Funakubo H, Suzuki M, et al. Increased expression of the adipocytokine omentin in the epicardial adipose tissue of coronary artery disease patients. Atherosclerosis 2016; 251:299–304.

    Article  CAS  Google Scholar 

  22. Kazama K, Usui T, Okada M, Hara Y, Yamawaki H. Omentin plays an antiinflammatory role through inhibition of TNF-α-induced superoxide production in vascular smooth muscle cells. Eur J Pharmacol 2012; 686:116–123.

    Article  CAS  Google Scholar 

  23. Zhong X, Li X, Liu F, Tan H, Shang D. Omentin inhibits TNF-α-induced expression of adhesion molecules in endothelial cells via ERK/NF-κB pathway. Biochem Biophys Res Commun 2012; 425:401–406.

    Article  CAS  Google Scholar 

  24. Booth A, Magnuson A, Fouts J, Foster MT. Adipose tissue: an endocrine organ playing a role in metabolic regulation. Horm Mol Biol Clin Investig 2016; 26:25–42.

    CAS  PubMed  Google Scholar 

  25. Karrasch T, Schaeffler A. Adipokines and the role of visceral adipose tissue in inflammatory bowel disease. Ann Gastroenterol 2016; 29:424.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Gastroenterology, Hepatology and Endoscopy Unit, Faculty of Medicine, Mansoura University, Ahmad Maher Street, 6th October Street, Mansoura, 35511, Egypt

    Mohammed A. Mohammed MD

  2. Department of Histology and Cell Biology, Faculty of Medicine, Mansoura University, Mansoura, Egypt

    Nesreen M. Omar

Authors
  1. Mohammed A. Mohammed MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nesreen M. Omar
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mohammed A. Mohammed MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mohammed, M.A., Omar, N.M. Serum omentin-1 as a predictor of activity in Crohn’s disease. Egypt J Intern Med 31, 514–521 (2019). https://doi.org/10.4103/ejim.ejim_82_19

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_82_19

Keywords